Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
- Conditions
- Neoplasms
- Interventions
- Drug: BIBW 2992 (Afatinib)
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT00748709
- Locations
- ๐บ๐ธ
1200.26.12 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
๐บ๐ธ1200.26.11 Boehringer Ingelheim Investigational Site, Denver, Colorado, United States
๐บ๐ธ1200.26.2 Boehringer Ingelheim Investigational Site, New York, New York, United States
Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks
- Conditions
- Migraine Disorders
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT00743015
- Locations
- ๐ง๐ช
1246.21.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium
๐ฉ๐ช1246.21.49001 Boehringer Ingelheim Investigational Site, Berlin, Germany
A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 227
- Registration Number
- NCT00740051
- Locations
- ๐บ๐ธ
1218.50.10011 Boehringer Ingelheim Investigational Site, Peoria, Arizona, United States
๐บ๐ธ1218.50.10002 Boehringer Ingelheim Investigational Site, Eugene, Oregon, United States
๐ต๐ญ1218.50.63007 Boehringer Ingelheim Investigational Site, Pasay, Philippines
Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 510
- Registration Number
- NCT00737100
- Locations
- ๐บ๐ธ
205.339.021 Boehringer Ingelheim Investigational Site, Miami, Florida, United States
๐บ๐ธ205.339.024 Boehringer Ingelheim Investigational Site, Cleveland, Ohio, United States
๐บ๐ธ205.339.022 Boehringer Ingelheim Investigational Site, Indianapolis, Indiana, United States
PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.
- Conditions
- HIV Infections
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 280
- Registration Number
- NCT00736502
- Locations
- ๐ต๐ฑ
Boehringer Ingelheim Investigational Site 12, Krakรณw, Poland
๐ฆ๐นBoehringer Ingelheim Investigational Site 3, Salzburg, Austria
๐ฆ๐นBoehringer Ingelheim Investigational Site 1, Graz, Austria
Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: linagliptine 5 mgDrug: linagliptine 5 mg and pioglitazone 30 mg
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2122
- Registration Number
- NCT00736099
- Locations
- ๐บ๐ธ
1218.40.10010 Boehringer Ingelheim Investigational Site, Hollywood, Florida, United States
๐บ๐ธ1218.40.10018 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
๐ฌ๐ท1218.40.30007 Boehringer Ingelheim Investigational Site, Athens, Greece
Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 41
- Registration Number
- NCT00730925
- Locations
- ๐ง๐ช
1200.41.32003 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium
๐ง๐ช1200.41.32006 Boehringer Ingelheim Investigational Site, Namur, Belgium
๐ง๐ช1200.41.32007 Boehringer Ingelheim Investigational Site, Charleroi, Belgium
Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2009-08-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT00730821
- Locations
- ๐บ๐ธ
1239.1.1 Boehringer Ingelheim Investigational Site, Tampa, Florida, United States
๐บ๐ธ1239.1.2 Boehringer Ingelheim Investigational Site, Detroit, Michigan, United States
๐บ๐ธ1239.1.3 Boehringer Ingelheim Investigational Site, Scottsdale, Arizona, United States
BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma
- First Posted Date
- 2008-08-04
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 151
- Registration Number
- NCT00727506
- Locations
- ๐บ๐ธ
1200.36.0007 Boehringer Ingelheim Investigational Site, Charleston, South Carolina, United States
๐จ๐ฆ1200.36.1011 Boehringer Ingelheim Investigational Site, Halifax, Nova Scotia, Canada
๐จ๐ฆ1200.36.1010 Boehringer Ingelheim Investigational Site, Winnipeg, Manitoba, Canada
Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis
- Conditions
- Pulmonary Disease, Chronic ObstructiveBronchitis, Chronic
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00726479
- Locations
- ๐บ๐ธ
1219.4.01004 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States
๐ซ๐ท1219.4.3306B Boehringer Ingelheim Investigational Site, Bethune Cedex, France
๐ซ๐ท1219.4.3303A Boehringer Ingelheim Investigational Site, Montpellier, France